Andrea Castillo
Family · Las Vegas, NVNPI 1104476647
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.1% of the total across 124 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 14.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,809, 2.9 times the $980 reported in 2021. Among family clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 124 payments — averaging $38.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$694
- Novo Nordisk$527
- AbbVie$437
- Lilly USA, LLC$349
- Amgen$336
- Dexcom, Inc.$321
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,72999%
- Education$451%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $694 |
| Novo Nordisk | 13 | $527 |
| AbbVie | 16 | $437 |
| Lilly USA, LLC | 8 | $349 |
| Amgen | 7 | $336 |
| Dexcom, Inc. | 6 | $321 |
| Biohaven Pharmaceuticals, Inc. | 6 | $278 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $218 |
| Edwards Lifesciences | 2 | $203 |
| Bayer | 2 | $139 |
| Pfizer | 6 | $132 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| UCB, Inc. | 1 | $125 |
| Viiv Healthcare Company | 1 | $120 |
| Otsuka America Pharmaceutical, Inc. | 4 | $110 |
| Merz North America, Inc. | 2 | $87 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Boston Scientific | 1 | $54 |
| ANI Pharmaceuticals, Inc. | 2 | $52 |
| Forte Bio-pharma LLC | 2 | $50 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Nalu Medical, Inc. | 1 | $25 |
| Astellas Pharma US Inc | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Corcept Therapeutics | 1 | $22 |
| Inogen, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| Viatris Specialty LLC | 1 | $20 |
| Almatica Pharma LLC | 1 | $19 |
| Bristol Myers Squibb | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Biotronik NRO, Inc. | 1 | $17 |
| Gilead | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Biodelivery Sciences International, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$251
- Ozempic$239
- QULIPTA$148
- UBRELVY$148
- NURTEC ODT$125
- QUVIVIQ$125
- DEXCOM G7 GSS (161)$125
- DEXCOM STELO GLUCOSE BIOSENSOR$125
- Nayzilam$125
- Repatha$125
- Kerendia$122
- AIRSUPRA$122
- ZEPBOUND$120
- APRETUDE$120
- DEXCOM G6 TRANSMITTER$118
- JARDIANCE$113
- SAPIEN 3 Ultra RESILIA$109
- RELISTOR$105
- RYBELSUS$102
How this compares
$4,774 in reported general payments places this provider in the 90th percentile of 1,501 family providers in Nevada.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 33 | $39,233 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 17 | $439 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $414 |
| Zolpidem Tartrate | 39 | $334 |
| Amlodipine Besylate | 30 | $273 |
| Gabapentin | 12 | $262 |
| Atorvastatin Calcium | 25 | $231 |
| Levothyroxine Sodium | 29 | $219 |
| Temazepam | 13 | $186 |
| Metformin Hcl | 24 | $177 |
| Lisinopril | 16 | $171 |
| Diazepam | 12 | $169 |
| Alprazolam | 36 | $164 |
| Omeprazole | 13 | $137 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 17 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $527 | $39,23333 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,501 family providers in Nevada.
Other family in Las Vegas
- Hollie TylerLas Vegas$118K
- John PhoenixLas Vegas$107K
- Jon FaillaLas Vegas$74K
- Alex LapasaranLas Vegas$50K
- Erin WilkinsonLas Vegas$43K
- Anna Melisa Lopez-SanglayLas Vegas$42K
- Kelly PapeshLas Vegas$28K
- Bernard BlanksLas Vegas$26K
- Hillary DursteinLas Vegas$21K
- Victoria HughesLas Vegas$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.